GSK's Blenrep Approved by UK MHRA for Multiple Myeloma Treatment
CompanyDrug

GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment

Salubris Pharma's YOLT-101 Gene Editing Drug Accepted for NMPA Review
CompanyDrug

Salubris Pharma’s YOLT-101 Gene Editing Drug Accepted for NMPA Review

Hansoh's HS-20093 ADC Earns BTD for Advanced NSCLC from China's NMPA
CompanyDrug

Hansoh’s HS-20093 ADC Earns BTD for Advanced NSCLC from China’s NMPA

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial
CompanyDeals

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial

Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors
CompanyDrug

Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors

Avistone's Vebreltinib and PLB1004 Receive CDE Breakthrough Therapy Designation for NSCLC
CompanyDrug

Avistone’s Vebreltinib and PLB1004 Receive CDE Breakthrough Therapy Designation for NSCLC

Shanghai Pharmaceuticals' RMB 4.66 Billion M&A Fund Completes AMAC Registration
CompanyDeals

Shanghai Pharmaceuticals’ RMB 4.66 Billion M&A Fund Completes AMAC Registration

Zhaoke Ophthalmology Signs Distribution Agreements with Thailand's Interpharma for Myopia and Presbyopia Treatments
CompanyDeals

Zhaoke Ophthalmology Signs Distribution Agreements with Thailand’s Interpharma for Myopia and Presbyopia Treatments

Eisai and Biogen Win EU Approval for Leqembi in Early Alzheimer's Disease
CompanyDrug

Eisai and Biogen Win EU Approval for Leqembi in Early Alzheimer’s Disease

Jiangsu Wuzhong Pharma Faces Forced Delisting After CSRC Investigation
Company

Jiangsu Wuzhong Pharma Faces Forced Delisting After CSRC Investigation

Sichuan Biokin's BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors
CompanyDrug

Sichuan Biokin’s BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors

Da Ren Tang Sells Stake in Tianjin Shike to Haleon for RMB 1.623 Billion
CompanyDeals

Da Ren Tang Sells Stake in Tianjin Shike to Haleon for RMB 1.623 Billion